Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15648240 | 0.83 | — | — | |
| SCHEMBL15218488 | 0.83 | — | — | |
| SCHEMBL2568929 | 0.81 | MEN1 (0.50) | SPHK2SPHK1 | |
| SCHEMBL1945695 | 0.81 | — | — | |
| SCHEMBL15237277 | 0.81 | — | — | |
| SCHEMBL9778987 | 0.77 | ALDH1A1 (0.39) | — | |
| SCHEMBL13004398 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL5717300 | 0.74 | SPHK2 (0.31) | SPHK2SPHK1 | |
| SCHEMBL56461 | 0.74 | — | — | |
| SCHEMBL56781 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024056805-A1 | NEW PET TRACER FOR IMAGING OF THE FUNCTIONAL HEPATIC RESERVE | MEDIZINISCHE UNIVERSITÄT INNSBRUCK (AT) | 2024-03-21 | — | — | WO | disclosed |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | KYOWA KIRIN CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| EP-3137115-B1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-9850147-B2 | Functional polymer membrane and method of producing the same | FUJIFILM CORPORATION (JP) | 2017-12-26 | — | — | US | disclosed |
| EP-2902097-B1 | FUNCTIONAL POLYMER MEMBRANE AND METHOD FOR ITS PRODUCTION | FUJIFILM CORP (JP) | 2017-11-29 | — | — | EP | disclosed |
| EP-2896636-B1 | CURABLE COMPOSITION AND IMAGE-FORMING METHOD | FUJIFILM CORP (JP) | 2017-09-27 | — | — | EP | disclosed |
| EP-2350077-B1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS LTD (GB) | 2016-01-27 | — | — | EP | disclosed |
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | ENTASIS THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
| US-9139747-B2 | Image forming method | FUJIFILM CORPORATION (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20150259227-A1 | FUNCTIONAL POLYMER MEMBRANE AND METHOD OF PRODUCING THE SAME | FUJIFILM CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
| US-20150191613-A1 | INK COMPOSITION, INK SET, AND IMAGE FORMATION METHOD | FUJIFILM CORPORATION (JP) | 2015-07-09 | — | — | US | disclosed |
| US-9040528-B2 | Chemical compounds 542 | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | ASTRAZENECA AB (SE) | 2014-05-08 | — | — | US | disclosed |
| US-8658641-B2 | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2014-02-25 | — | — | US | disclosed |
| US-20130222501-A1 | IMAGE FORMING METHOD | FUJIFILM CORPORATION (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| EP-2350077-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010043893-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | MRPL21, CFTR, CYP3A43 | SPHK2 2459/4885SPHK1 3323/4885 |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | SDHB, SDHA, RORC | SPHK2 1963/4885SPHK1 2015/4885 |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | LIPA, LIPC, PNLIP | SPHK2 1541/4885SPHK1 1300/4885 |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | MRPL21, CFTR, CYP3A43 | SPHK2 2459/4885SPHK1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.